Pfizer priced the initial public offering of 86.1 million shares of its animal health business, which will be spun out in a new company called Zoetis, at $22 to $25 per share in an amended S-1 form filed with the US Securities and Exchange Commission (SEC) on 17 January, valuing the company at about $11.8 billion at the mid-point of its price range, or $23.50 per share.
Zoetis IPO values Pfizer animal health business at up to $15.8bn
Pfizer priced the initial public offering of 86.1 million shares of its animal health business, which will be spun out in a new company called Zoetis, at $22 to $25 per share in an amended S-1 form filed with the US Securities and Exchange Commission (SEC) on 17 January, valuing the company at about $11.8 billion at the mid-point of its price range, or $23.50 per share.
More from India
More from Focus On Asia
• By
Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, Scrip hears.
• By
AstraZeneca logs growth in Japan despite a big reimbursement price cut for one of its top sellers and expects 40 approvals in the country over the next six years.
• By
GNT Pharma prepares for the first listing of a Korean biotech on Nasdaq, while others sign major global out-licensing deals with large multinational partners.